SPR Therapeutics raised $ eight million on a Collection C $ 20 million sequence of financing that started January 19, in accordance with a SEC report.
The corporate's Cleveland-based Dash Peripheral Nerve Stimulation System is FDA authorised for persistent and acute ache, together with postoperative and post-traumatic ache. The product was launched in November 2018 for the therapy of advanced regional ache syndrome, with persistent limb ache that may be attributable to trauma, harm or surgical procedure.
The corporate additionally lately introduced the appointment of Peter Staats, MD, as Chief Medical Advisor. Based on a press release from the corporate, Staats brings almost three a long time of entrepreneurial expertise in ache administration and neuromodulation expertise.
Staats was president of the American Society of Interventional Ache Physicians, the North American Neuromodulation Society, the New Jersey Society of Interventional Ache Physicians and the Southern Ache Society. He has additionally co-edited or written 10 manuals on ache administration. near 300 articles, guide chapters and abstracts on the analysis and administration of advanced pain-related issues.
Staats based the Division of Ache Drugs at Johns Hopkins College Faculty of Drugs in 1994 and served as its director for 10 years. He was then founding companion of New Jersey's premier ache facilities, lately merged with the Nationwide Backbone and Ache Facilities.
Staats will advise SPR within the areas of affected person choice, medical trial design, doctor coaching, product enchancment and reimbursement methods, amongst others, the corporate mentioned.
SPR Therapeutics mentioned in October that it obtained $ 10 million from two new grants and a contract from the US Division of Protection, all to help his percutaneous peripheral nerve stimulation remedy supposed to be a non-opioid ache reduction therapy for acute and persistent ache.
The put up workplace SPR Therapeutics Ache Remedy Agency Seeks $ 20 Million appeared first on MassDevice.